4-Chlorophenylacetic acid
Based on 1 Customer Validation
4-Chlorophenylacetic acid is an aromatase antagonist. 4-Chlorophenylacetic acid inhibits estrogen-induced breast tumorigenesis by blocking estrogen conversion. 4-Chlorophenylacetic acid also serves as the sole carbon and energy source for Pseudomonas sp. CBS3; it is degraded via dechlorination and aromatic ring cleavage pathways, and induces the synthesis of protocatechuate 2,3-dioxygenase. 4-Chlorophenylacetic acid can be applied to studies related to estrogen-induced breast tumors and bacterial degradation pathways.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.94%
- CAS No.: 1878-66-6
- Formule: C8H7ClO2
- Masse moléculaire:170.59
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-N1902
4-Hydroxyphenylacetic acidEndogenous Metabolite -
HY-W001080
3,4-Dihydroxybenzeneacetic acid -
HY-W001083
3-Hydroxyphenylacetic acidFlavonoid Metabolite -
HY-113283
Homogentisic acidBrain-damaging Agent -
HY-W001080R
3,4-Dihydroxybenzeneacetic acid (Standard) -
HY-N1902R
4-Hydroxyphenylacetic acid (Standard)Endogenous Metabolite -
HY-W015590
2-Hydroxyphenylacetic acidPhenylalanine/Tyrosine Metabolite -
HY-113283R
Homogentisic acid (Standard)Endogenous Metabolite -
HY-W001146
3-Chloro-4-hydroxyphenylacetic acidBuilding Block -
HY-W015590R
2-Hydroxyphenylacetic acid (Standard)Standard Of 2-Hydroxyphenylacetic Acid -
HY-W001083R
3-Hydroxyphenylacetic acid (Standard)Standard of 3-Hydroxyphenylacetic acid -
HY-W010062R
4-Chlorophenylacetic acid (Standard)Reference Standard
Activité biologique
Description
IC50 & Target
[1]|
Aromatase |
In Vitro
4-Chlorophenylacetic acid (0.05% (0.5 g/L); growth to late log phase) induces homoprotocatechuate 2,3-dioxygenase with a specific activity of 0.061 μmol/min/mg in Pseudomonas sp. strain CBS3, but does not induce enzymes of the 4-hydroxyphenylacetate degradation pathway[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1878-66-6
-
Appearance Solid
-
Masse moléculaire 170.59
-
Formule C8H7ClO2
-
Color White to off-white
-
SMILES
ClC1=CC=C(CC(O)=O)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (586.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
-
Fiche technique (292 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Aputen AD, et al. Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates. Molecules (Basel, Switzerland). 2022 Oct 21;27(20):7120. [Content Brief]
[3]. Klages U, et al. Degradation of 4-chlorophenylacetic acid by a Pseudomonas species. Journal of bacteriology. 1981 Apr;146(1):64-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.8620 mL | 29.3100 mL | 58.6201 mL | 146.5502 mL |
| 5 mM | 1.1724 mL | 5.8620 mL | 11.7240 mL | 29.3100 mL | |
| 10 mM | 0.5862 mL | 2.9310 mL | 5.8620 mL | 14.6550 mL | |
| 15 mM | 0.3908 mL | 1.9540 mL | 3.9080 mL | 9.7700 mL | |
| 20 mM | 0.2931 mL | 1.4655 mL | 2.9310 mL | 7.3275 mL | |
| 25 mM | 0.2345 mL | 1.1724 mL | 2.3448 mL | 5.8620 mL | |
| 30 mM | 0.1954 mL | 0.9770 mL | 1.9540 mL | 4.8850 mL | |
| 40 mM | 0.1466 mL | 0.7328 mL | 1.4655 mL | 3.6638 mL | |
| 50 mM | 0.1172 mL | 0.5862 mL | 1.1724 mL | 2.9310 mL | |
| 60 mM | 0.0977 mL | 0.4885 mL | 0.9770 mL | 2.4425 mL | |
| 80 mM | 0.0733 mL | 0.3664 mL | 0.7328 mL | 1.8319 mL | |
| 100 mM | 0.0586 mL | 0.2931 mL | 0.5862 mL | 1.4655 mL |
4-Chlorophenylacetic acid Related Classifications
HY-W010062 Related Classifications
Powered by Bioz
Keywords
- 4-Chlorophenylacetic acid
- 1878-66-6
- Cytochrome P450
- Estrogen Receptor/ERR
- aromatase
- homoprotocatechuate 2
- 3-dioxygenase
- homoprotocatechuic acid
- platinum(IV) complex
- estrogen-induced mammary tumorigenesis
- meta-cleavage pathway
- estrogen signalling
- Pseudomonas sp. strain CBS3
- chlorohydroxyphenylacetic acid isomers
- androgen-to-estrogen conversion
- Inhibitor
- inhibitor
- inhibit